Clinical Trial: A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07872306) titled 'A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)' on Sept. 22.

Brief Summary: This is a two-part, Phase 2, randomized, placebo-controlled, double-blind study, followed by a randomized active treatment period, to evaluate the safety and efficacy of orally administered forazapadin (SAT-3247) in adult participants with FSHD

Study Start Date: Dec. 15

Study Type: INTERVENTIONAL

Condition: Facioscapulohumeral Muscular Dystrophy (FSHD)

Intervention: DRUG: forazapadin

Forazapadin (SAT 3247) is a potent, orally available, muscle penetrant, small m...